Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP: RHHBY )

42.86 -0.70 (-1.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,994,620
Open 42.93
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 43.56
Today's Range 42.66 - 43.11
52wk Range 29.20 - 43.96
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped
Ignore the noise in GLP-1 stocks. Find the best value instead. 
Via The Motley Fool
Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion
The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug. 
Via Investor's Business Daily

Performance

YTD
+22.67%
+22.67%
1 Month
+7.47%
+7.47%
3 Month
+19.06%
+19.06%
6 Month
+14.81%
+14.81%
1 Year
+21.93%
+21.93%

More News

Read More
Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs
Via Benzinga
FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis
From Genentech
Via Business Wire
FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults
From Genentech
Via Business Wire
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
Via Benzinga
Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies
From Genentech
Via Business Wire
NovoCure Q4 EPS Misses, Revenue Matches
Via The Motley Fool
Viking Therapeutics: Could GLP-1 Maker Be Acquired Pre-Approval?
Via MarketBeat
Exposures Product Safety
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
New England Journal of Medicine Publishes New Data for Genentech’s Gazyva Which Shows Superiority Over Standard Therapy in People With Active Lupus Nephritis
From Genentech
Via Business Wire
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
From Genentech
Via Business Wire
Teva's Duvakitug Set To Shake Up IBD Treatment, Analyst Highlights Competitive Data
Via Benzinga
Genentech’s Itovebi Demonstrated Statistically Significant and Clinically Meaningful Overall Survival Benefit in a Certain Type of HR-Positive Advanced Breast Cancer
From Genentech
Via Business Wire
Sarepta Therapeutics' Duchenne Gene Therapy Shows Sustained Benefits And Disease Stabilization At Two Years
Via Benzinga
Legal Marijuana Linked To Drop In Anxiety Medications: What It Means For Pharma Giants
Via Benzinga
Topics Cannabis
Exposures Cannabis
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
Via Benzinga
Exposures Product Safety
Regeneron Pharmaceuticals Slumps As Sales Of High-Dose Eylea Disappoint
Via Investor's Business Daily
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
Sangamo Therapeutics Stock Plunges As Pfizer Terminates Hemophilia Gene Therapy Pact
Via Benzinga
Roche CEO Reassures No Job Cuts Despite Challenges: Report
Via Benzinga
Topics Workforce
Exposures Layoff
Prothena Catapults, Flashing A Bullish Sign, On Promise In Parkinson's Disease
Via Investor's Business Daily
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Via Benzinga
Genentech’s Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson’s Disease
From Genentech
Via Business Wire
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.